| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae38902af0c0a7dbd91491c5efe691d6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55544
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-295
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 |
| filingDate |
2014-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04cd521e6375861ad0b8d65e5857c2d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba395d8f59c665532edcd2b73b9c5fcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1c097077ada639e5b3ceac03d8bfffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19178854e2296b57b37c03a48996617d |
| publicationDate |
2017-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EA-027463-B1 |
| titleOfInvention |
POLIVALENT VACCINE AGAINST FLU ON THE BASIS OF A HYBRID PROTEIN |
| abstract |
In the invention, the challenge to be solved is the lack of a safe, effective universal flu vaccine. The solution includes a vaccine based on a fusion protein consisting of antigenic determinants of hemoagglutinins of influenza A and B viruses and fragments of flagellin acting as a safe adjuvant (SEQ ID NO: 1) connected by flexible bridges that can be used to prevent influenza caused by known strains influenza viruses A and B, as well as possible reassortants. Demonstrated safety, efficacy, polyvalence and prophylactic effect. Using this vaccine will provide universal protection against influenza. |
| priorityDate |
2013-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |